Market Access/ News/ News Final NICE rejection for Biomarin’s childhood rare disease drug George Underwood Batten disease, BioMarin, Brineura, cerliponase alfa, CLN2 0 Comment After a year of negotiations NICE has confirmed that it is still unable to recommend Biomarin’s Batten disease Share X Final NICE rejection for Biomarin’s childhood rare disease drug https://pharmaphorum.com/news/final-nice-rejection-for-biomarins-childhood-rare-disease-drug/
Batten disease, BioMarin, Brineura, cerliponase alfa, CLN2
0 Comment
